中文摘要：

以3株抗肿瘤活性新化合物产生菌放线菌野生株YN17707（陆地）、18522（陆地）和007（海洋）为出发菌,用核糖体工程抗生素抗性筛选技术,改造次级产物代谢生产能力。通过链霉素抗性筛选,得到突变株212株,经发酵产物的TLC和HPLC分析,高产原始菌所产化合物的突变株87株（41%）,可产新产物的突变株22株（10%）。在18522的108株突变株中,高产突变株达53.7%（58株）,产新产物突变株达11.1%（12株）,链霉素抗性筛选对18522的效果较为理想。

英文摘要：

Three actinomycetic strains,007（marine）,YN17707 and 18522（both terrestrial）,which produce new compounds with antitumor activity respectively,were used as initial strains to alter their secondary metabolism by ribosome engineering technology.Total 212 of streptomycin-resistant（str） mutants were obtained from 007,YN17707 and 18522 respectively by single colony isolation on streptomycin-containing plates according to the method for obtaining drug-resistant mutants in ribosome engineering.The initial and mutant strains were fermented under the same condition and their extracts were prepared in a same manner.By TLC and HPLC analysis of the extracts,it was shown that the 87 str mutants（41% of total mutants） have acquired the enhanced productivity of the new compound being produced originally by their parent strains and the 22 str mutants（10% of total mutants） could produce metabolites being newly produced.Among the 108 str mutants from 18522,the mutants with enhanced productivity of actinolactomycin,a new compound that produced originally by 18522,possessed 53.7%（the 58 mutants） and the 11.1%（the 12 mutants） of total mutants newly produced the metabolites that could not be produced by the parent strain 18522.